Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $33.3333.

Several research firms have recently issued reports on GLUE. JPMorgan Chase & Co. raised their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Guggenheim raised their price objective on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st.

Monte Rosa Therapeutics Trading Down 6.0%

NASDAQ:GLUE traded down $1.48 during midday trading on Friday, hitting $23.04. 1,718,269 shares of the company traded hands, compared to its average volume of 1,603,364. The firm’s fifty day moving average is $19.81 and its 200-day moving average is $19.13. Monte Rosa Therapeutics has a 12-month low of $4.12 and a 12-month high of $25.77. The firm has a market capitalization of $1.95 billion, a P/E ratio of -15.57 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. On average, research analysts expect that Monte Rosa Therapeutics will post -1.23 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the transaction, the insider owned 67,845 shares in the company, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Filip Janku sold 5,407 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a total value of $132,471.50. Following the completion of the transaction, the insider directly owned 60,612 shares in the company, valued at $1,484,994. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 81,778 shares of company stock valued at $1,768,581 over the last quarter. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new stake in Monte Rosa Therapeutics in the 4th quarter valued at about $30,000. Russell Investments Group Ltd. purchased a new position in shares of Monte Rosa Therapeutics during the third quarter worth approximately $32,000. Lazard Asset Management LLC increased its position in shares of Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after acquiring an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.